Literature DB >> 22234791

Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic moyamoya angiopathy.

Markus Kraemer1, Peter A Horn, Constantin Roder, Nadia Khan, Rolf R Diehl, Peter Berlit, Falko M Heinemann.   

Abstract

BACKGROUND: The etiology and genetic susceptibility of Moyamoya angiopathy (MMA) (Moyamoya disease, Moyamoya syndrome and unilateral type of MMA) still remain unclear. In Asian patient cohorts several HLA markers were described to be associated with MMA, but in Caucasians very little is known about genetic susceptibility of this angiopathy.
METHOD: We analysed DNA of 33 Caucasian patients with MMA for HLA-A, HLA-B, HLA-DRB1, and HLA-DQB1 markers, respectively. HLA frequencies of all 33 patients with MMA were compared with HLA-frequencies of Caucasian controls. Additionally, subgroup analysis of 22 patients with Moyamoya disease (MMD) and 11 patients with unilateral type of MMA was performed.
FINDINGS: Significant association was observed for HLA-DRB1*03 and HLA-DRB1*13 in all 33 patients (P (c) < 0.001 and P (c) < 0.001, respectively). Moreover, HLA-A*02 (P (c) = 0.009); HLA-B*08 (P (c) = 0.009), and HLA-DQB1*03 (P (c) = 0.003) frequencies were higher in all patients with MMA when compared with the controls. In addition, in 22 patients with MMD a higher frequency of HLA-DRB1*03 (P (c) < 0.001) was observed when compared with controls.
CONCLUSIONS: The results of this study indicate a putative association of HLA markers with MMA in Caucasian patients. Further studies are needed to elucidate the role of human MHC in the pathogenesis of this angiopathy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22234791     DOI: 10.1007/s00701-011-1261-5

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  8 in total

Review 1.  Progress in moyamoya disease.

Authors:  Shuling Shang; Da Zhou; Jingyuan Ya; Sijie Li; Qi Yang; Yuchuan Ding; Xunming Ji; Ran Meng
Journal:  Neurosurg Rev       Date:  2018-06-18       Impact factor: 3.042

Review 2.  Single Nucleotide Polymorphism in Patients with Moyamoya Disease.

Authors:  Young Seok Park
Journal:  J Korean Neurosurg Soc       Date:  2015-06-30

Review 3.  Moyamoya disease and syndromes: from genetics to clinical management.

Authors:  Stéphanie Guey; Elisabeth Tournier-Lasserve; Dominique Hervé; Manoelle Kossorotoff
Journal:  Appl Clin Genet       Date:  2015-02-16

4.  Distinctive facial features in idiopathic Moyamoya disease in Caucasians: a first systematic analysis.

Authors:  Markus Kraemer; Quoc Bao Huynh; Dagmar Wieczorek; Brunilda Balliu; Barbara Mikat; Stefan Boehringer
Journal:  PeerJ       Date:  2018-06-27       Impact factor: 2.984

5.  Identification of HLA-DRB1*04:10 allele as risk allele for Japanese moyamoya disease and its association with autoimmune thyroid disease: A case-control study.

Authors:  Ryosuke Tashiro; Kuniyasu Niizuma; Seik-Soon Khor; Katsushi Tokunaga; Miki Fujimura; Hiroyuki Sakata; Hidenori Endo; Hidetoshi Inoko; Koetsu Ogasawara; Teiji Tominaga
Journal:  PLoS One       Date:  2019-08-14       Impact factor: 3.240

Review 6.  The Genetic Basis of Moyamoya Disease.

Authors:  R Mertens; M Graupera; H Gerhardt; A Bersano; E Tournier-Lasserve; M A Mensah; S Mundlos; P Vajkoczy
Journal:  Transl Stroke Res       Date:  2021-09-16       Impact factor: 6.829

7.  Analysis of HLA Variants and Graves' Disease and Its Comorbidities Using a High Resolution Imputation System to Examine Electronic Medical Health Records.

Authors:  Wen-Ling Liao; Ting-Yuan Liu; Chi-Fung Cheng; Yu-Pao Chou; Tzu-Yuan Wang; Ya-Wen Chang; Shih-Yin Chen; Fuu-Jen Tsai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-07       Impact factor: 5.555

Review 8.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.